文献速递关节外科

NarxCare评分大于300与初次全髋关节置换术后不良结局相关

NarxCare Scores Greater Than 300 Are Associated with Adverse Outcomes After Primary THA.
PubMed 文献 · Clin Orthop Relat Res · 2021-01-01

本研究回顾性分析2787例初次单侧全髋关节置换术患者,发现术前NarxCare评分(NCS)300-399与90天全因再入院、手术相关再入院、住院超过2天及非家庭出院 odds 升高相关;NCS 400-499还增加90天急诊就诊风险。NCS与不良结局呈剂量反应关系,但NCS不应作为手术拒绝的依据。

要点

  • NCS 300-399增加90天全因再入院(OR 2.0)、手术相关再入院(OR 3.3)、住院>2天(OR 2.2)及非家庭出院(OR 2.0)风险。
  • NCS 400-499还增加90天急诊就诊风险(OR 2.2)。
  • NCS可用于术前风险讨论,但不应作为手术禁忌依据。

核心结论

  • 术前处方药使用反映为较高NCS,与THA术后不良结局存在剂量反应关联。

研究设计与样本

  • 采用多变量回归分析和倾向性评分匹配比较(基于年龄、性别、种族、BMI、吸烟状态、CCI、保险状态、术前诊断和手术入路)。

主要发现

  • NCS 300-399与90天全因再入院(OR 2.0 [95% CI 1.1-3.3]; p=0.02)、手术相关再入院(OR 3.3 [95% CI 1.4-7.9]; p=0.006)、住院>2天(OR 2.2 [95% CI 1.5-3.2]; p<0.001)和非家庭出院(OR 2.0 [95% CI 1.3-3.1]; p=0.002) odds 升高相关。
  • NCS 400-499显示相似模式,并且90天急诊就诊 odds 升高(OR 2.2 [95% CI 1.2-3.9]; p=0.01)。
  • 活性阿片类药物处方与90天全因再入院(OR 1.002 [95% CI 1.001-1.004]; p=0.05)、手术相关再入院(OR 1.003 [95% CI 1.001-1.006]; p=0.02)、住院>2天(OR 1.003 [95% CI 1.002-1.005]; p<0.001)和非家庭出院(OR 1.002 [95% CI 1.001-1.003]; p=0.019)的关联效应量很小,不太可能具有临床意义。
  • 活性镇静剂使用与90天急诊就诊的关联同样很小(OR 1.002 [95% CI 1.001-1.004]; p=0.02),不太可能具有临床重要性。

关键数值与推荐

  • NCS 300-399:90天全因再入院OR 2.0(95% CI 1.1-3.3; p=0.02),手术相关再入院OR 3.3(95% CI 1.4-7.9; p=0.006),住院>2天OR 2.2(95% CI 1.5-3.2; p<0.001),非家庭出院OR 2.0(95% CI 1.3-3.1; p=0.002)。
  • NCS 400-499:90天急诊就诊OR 2.2(95% CI 1.2-3.9; p=0.01),其他结局与300-399相似。

临床怎么用

  • 外科医生可利用术前NCS启动以患者为中心的讨论,告知处方药使用模式(镇静剂、阿片类药物或兴奋剂)相关的术后风险。
  • 可启动跨学科方法来改善不良处方药使用模式,从而降低患者NCS。
  • NCS反映药物使用模式而非当前健康状况,不应作为手术拒绝或不合格的依据。

局限性

  • 回顾性研究设计。
  • 8%患者因缺失基线信息被排除,其BMI分布相似但年龄稍年轻且CCI较低。
  • NCS反映药物使用模式而非患者当前健康状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The association between preoperative prescription drug use (narcotics, sedatives, and stimulants) and complications and/or greater healthcare utilization (length of stay, discharge disposition, readmission, emergency department visits, and reoperation) after total joint arthroplasty has been established but not well quantified. The NarxCare score (NCS) is a weighted scalar measure of overall prescription opioid, sedative, and stimulant use. Higher scores reflect riskier drug-use patterns, which are calculated based on (1) the number of prescribing providers, (2) the number of dispensing pharmacies, (3) milligram equivalence doses, (4) coprescribed potentiating drugs, and (5) overlapping prescription days. The aforementioned factors have not been incorporated into association measures between preoperative prescription drug use and adverse events after THA. In addition, the utility of the NCS as a scalar measure in predicting post-THA complications has not been explored. QUESTIONS/PURPOSES: (1) Is the NarxCare score (NCS) associated with 90-day readmission, reoperation, emergency department visits, length of stay, and discharge disposition after primary THA; and are there NCS thresholds associated with a higher risk for those adverse outcomes if such an association exists? (2) Is there an association between the type of preoperative active drug prescription and the aforementioned outcomes? METHODS: Of 3040 primary unilateral THAs performed between November 2018 and December 2019, 92% (2787) had complete baseline information and were subsequently included. The cohort with missing baseline information (NCS or demographic/racial determinants; 8%) had similar BMI distribution but slightly younger age and a lower Charlson Comorbidity Index (CCI). Outcomes in this retrospective study of a longitudinally maintained institutional database included 90-day readmissions (all-cause, procedure, and nonprocedure-related), reoperations, 90-day emergency department (ED) visits, prolonged length of stay (> 2 days), and discharge disposition (home or nonhome). The association between the NCS category and THA outcomes was analyzed through multivariable regression analyses and a confirmatory propensity score-matched comparison based on age, gender, race, BMI, smoking status, CCI, insurance status, preoperative diagnosis, and surgical approach, which removed significant differences at baseline. A similar regression model was constructed to evaluate the association between the type of preoperative active drug prescription (opioids, sedatives, and stimulants) and adverse outcomes after THA. RESULTS: After controlling for potentially confounding variables like age, gender, race, BMI, smoking status, CCI, insurance status, preoperative diagnosis, and surgical approach, an NCS of 300 to 399 was associated with a higher odds of 90-day all-cause readmission (odds ratio 2.0 [95% confidence interval 1.1 to 3.3]; p = 0.02), procedure-related readmission (OR 3.3 [95% CI 1.4 to 7.9]; p = 0.006), length of stay > 2 days (OR 2.2 [95% CI 1.5 to 3.2]; p < 0.001), and nonhome discharge (OR 2.0 [95% CI 1.3 to 3.1]; p = 0.002). A score of 400 to 499 demonstrated a similar pattern, in addition to a higher odds of 90-day emergency department visits (OR 2.2 [95% CI 1.2 to 3.9]; p = 0.01). After controlling for potentially confounding variables like age, gender, race, BMI, smoking status, CCI, insurance status, preoperative diagnosis, and surgical approach, we found no clinically important association between an active opioid prescription and 90-day all-cause readmission (OR 1.002 [95% CI 1.001 to 1.004]; p = 0.05), procedure-related readmission (OR 1.003 [95% CI 1.001 to 1.006]; p = 0.02), length of stay > 2 days (OR 1.003 [95% CI 1.002 to 1.005]; p < 0.001), or nonhome discharge (OR 1.002 [95% CI 1.001 to 1.003]; p = 0.019); the large size of the database allowed us to find statistical associations, but the effect sizes are so small that the finding is unlikely to be clinically meaningful. A similarly small association that is unlikely to be clinically important was found between active sedative use and 90-day ED visits (OR 1.002 [95% CI 1.001 to 1.004]; p = 0.02). CONCLUSION: Preoperative prescription drug use, as reflected by higher NCSs, has a dose-response association with adverse outcomes after THA. Surgeons may use the preoperative NCS to initiate and guide a patient-centered discussion regarding possible postoperative risks associated with prescription drug-use patterns (sedatives, opioids, or stimulants). An interdisciplinary approach can then be initiated to mitigate unfavorable patterns of prescription drug use and subsequently lower patient NCSs. However, given its nature and its reflection of drug-use patterns rather than patients' current health status, the NCS does not qualify as a basis for surgical denial or ineligibility. LEVEL OF EVIDENCE: Level III, diagnostic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Emara AK, Grits D, Klika AK, et al. NarxCare Scores Greater Than 300 Are Associated with Adverse Outcomes After Primary THA. Clin Orthop Relat Res. 2021. PMID: 33835083. doi:10.1097/CORR.0000000000001745

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。